Search results for "CHOD"

showing 10 items of 372 documents

Salmeterol Xinafoate (SX) loaded into mucoadhesive solid lipid microparticles for COPD treatment

2019

Chronic obstructive pulmonary disease (COPD) is one of the main health problems worldwide. It is characterised by chronic inflammation in the lungs that leads to progressive, chronic, largely irreversible airflow obstruction. The use of long-acting β agonists remain today the frontline treatment for COPD with the aim of minimizing side effects and enhancing therapeutic usefulness. To this purpose, in this paper, mucoadhesive solid lipid microparticles (SLMs) containing a long-acting β-2 agonist, Salmeterol Xinafoate (SX) were prepared, characterised (size, z-potential, aerodynamic diameter, turbidimetric evaluations, drug loading and entrapping efficiency) and tested in a model of bronchial…

3003AgonistDrugAlginatesCell Survivalmedicine.drug_classmedia_common.quotation_subjectSodium alginate polymerPharmaceutical ScienceChronic obstructive pulmonary disease (COPD)Inflammation02 engineering and technologyPharmacology030226 pharmacology & pharmacyCell LinePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinecAMPmedicineHumansAerodynamic diameterAdrenergic beta-2 Receptor AgonistsSalmeterol Xinafoatemedia_commonDrug CarriersCOPDInhalationChemistryTherapeutic effectAdhesiveness021001 nanoscience & nanotechnologymedicine.diseaseLipidsSALMETEROL XINAFOATEBronchodilator Agentsrespiratory tract diseasesSalmeterol Xinafoate (SX)MucusAerodynamic diametermedicine.symptom0210 nano-technologyInternational Journal of Pharmaceutics
researchProduct

Symptom variability and control in COPD: Advantages of dual bronchodilation therapy

2017

Abstract Background Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by usually progressive development of airflow obstruction that is not fully reversible. While most patients will experience symptoms throughout the day or in the morning upon awakening, many patients do not experience their symptoms as constant but report variability in symptoms during the course of the day or over time. Symptom variability adversely affects patients' health status and increases the risk of COPD exacerbations. Methods We examined data from the literature on symptom variability and control in patients with COPD, with focus on the use of inhaled bronchodilator therapy wi…

Aclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Pulmonary and Respiratory MedicineAclidiniumHealth StatusVital CapacityHealth StatuPulmonary Disease Chronic Obstructive0302 clinical medicineForced Expiratory VolumeFormoterol FumarateBronchodilatorBronchodilationFormoterol030212 general & internal medicineAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital CapacityLung functionCOPDbiologyChronic obstructive pulmonary diseaseTropaneLamaBronchodilator AgentsMuscarinic AntagonistTreatment OutcomeInhalationAdministrationCombinationDisease ProgressionDrug Therapy CombinationDrugHumanmedicine.drugAdrenergic beta-2 Receptor AgonistPulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtymedicine.drug_classSymptom variabilitySocio-culturaleMuscarinic AntagonistsSettore MED/10 - Malattie Dell'Apparato RespiratorioDose-Response RelationshipPulmonary Disease03 medical and health sciencesDrug TherapyAdministration InhalationmedicineHumansIntensive care medicineAdrenergic beta-2 Receptor AgonistsBronchodilator AgentDose-Response Relationship Drugbusiness.industryMuscarinic antagonistDual bronchodilator therapymedicine.diseasebiology.organism_classificationLung functionrespiratory tract diseasesAclidinium; Chronic obstructive pulmonary disease; Dual bronchodilator therapy; Formoterol; Lung function; Symptom variability; Administration Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Dose-Response Relationship Drug; Drug Therapy Combination; Forced Expiratory Volume; Formoterol Fumarate; Health Status; Humans; Muscarinic Antagonists; Pulmonary Disease Chronic Obstructive; Quality of Life; Treatment Outcome; Tropanes; Vital Capacity; Pulmonary and Respiratory MedicineDual bronchodilation030228 respiratory systemQuality of LifeFormoterolbusinessTropanesRespiratory Medicine
researchProduct

Early management of COPD: Where are we now and where do we go from here? a delphi consensus project

2019

Fabiano Di Marco,1 Piero Balbo,2 Francesco de Blasio,3 Vittorio Cardaci,4 Nunzio Crimi,5 Giuseppe Girbino,6 Girolamo Pelaia,7 Pietro Pirina,8 Pietro Roversi,9 Pierachille Santus,10,11 Nicola Scichilone,12 Alessandro Vatrella,13 Patrizio Pasqualetti,14 Mauro Carone15 1Department of Health Sciences, University of Milan, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy; 2SC Malattie dell’Apparato Respiratorio, AOU Maggiore della Carità, Novara, Italy; 3Respiratory Medicine and Pulmonary Rehabilitation Section, Clinic Center S.p.A. Private Hospital, Department of Medicine and Health Sciences “V Tiberio”, University of Molise, Campobasso, It…

Adrenergic beta-2 Receptor AgonistPulmonary and Respiratory Medicinedrug combinationspractice guidelines as topicConsensuPredictive Value of Testbronchodilator therapy; dyspnea; italy; respiratory symptoms; adrenal cortex hormones; adrenergic beta-2 receptor agonists; adult; bronchodilator agents; consensus; delphi technique; drug combinations; early diagnosis; early medical intervention; evidence-based medicine; female; humans; italy; male; middle aged; muscarinic antagonists; practice guidelines as topic; predictive value of tests; pulmonary disease; chronic obstructive; surveys and questionnaires; treatment outcomeadrenal cortex hormonesSettore MED/10 - Malattie Dell'Apparato RespiratorioInternational Journal of Chronic Obstructive Pulmonary DiseasedyspnoeaAdrenal Cortex HormonePulmonary Disease Chronic ObstructivemaleDrug CombinationEarly Diagnosiitalymiddle agedSurveys and Questionnairehumansmuscarinic antagonistsBronchodilator AgentOriginal Researchearly medical interventionpulmonary diseaselcsh:RC705-779chronic obstructiveHealth Policyadultbronchodilator agentsEnvironmental and Occupational Healthrespiratory symptomsbronchodilator therapylcsh:Diseases of the respiratory systemdyspneaBronchodilator therapy; Dyspnea; Italy; Respiratory symptoms; Pulmonary and Respiratory Medicine; Health Policy; Public Health Environmental and Occupational Healthpredictive value of testsMuscarinic AntagonistfemaleconsensusRespiratory symptomsurveys and questionnairestreatment outcomePublic Healthdelphi techniqueadrenergic beta-2 receptor agonistsevidence-based medicineHumanearly diagnosis
researchProduct

Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma

2003

Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 µg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 µg/day (n…

AdultCyclopropanesMalePulmonary and Respiratory MedicineBudesonideAdolescentmedicine.drug_classAcetatesSulfidesFluticasone propionatechemistry.chemical_compoundDouble-Blind Methodimmune system diseasesAdministration InhalationHumansMedicineSingle-Blind MethodAnti-Asthmatic AgentsBudesonideMontelukastAgedAsthmaLeukotriene E4business.industryMiddle Agedmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeEditorialchemistryAnesthesiaQuinolinesCorticosteroidDrug Therapy CombinationFemaleOnset of actionSalmeterolbusinessmedicine.drugThorax
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

Analysis of interleukin-6 and interleukin-8 in lung transplantation: correlation with nitric oxide administration.

2008

Introduction and Objectives. Primary graft dysfunction (PGD) following lung transplantation (LT) is associated with an activation of the inflammatory cascade and release of cytokines. Inhaled nitric oxide (iNO) provides specific pulmonary vasodilatation and improves oxygenation. Our objective was to verify whether administering iNO to LT patients modified the blood and bronchoalveolar lavage (BAL) interleukin (IL)-6 and -8 levels in the event of PGD. Materials and Methods. Thirty-two LT patients were randomized to the iNO treatment or the control group. Patients in the first group were given 10 ppm of iNO from the start of LT until 48 hours afterward. BAL and peripheral arterial blood sampl…

AdultGraft Rejectionmedicine.medical_specialtyAdolescentmedicine.medical_treatmentNitric OxideGastroenterologyNitric oxidechemistry.chemical_compoundYoung AdultPostoperative ComplicationsInternal medicineAdministration InhalationmedicineLung transplantationHumansInterleukin 6AgedInflammationTransplantationLungmedicine.diagnostic_testbiologybusiness.industryInterleukin-6Interleukin-8Interleukinrespiratory systemMiddle AgedBronchodilator AgentsTransplantationBronchoalveolar lavagemedicine.anatomical_structurechemistryAnesthesiabiology.proteinArterial bloodSurgerybusinessLung TransplantationTransplantation proceedings
researchProduct

Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effects of magnesium in asthma

1998

1.Increased bronchial smooth muscle contractility with consequent bronchial hyperreactivity are characteristic physiopathological events of asthma. Since magnesium intervenes in calcium transport mechanisms and intracellular phosphorylation reactions, it constitutes an important determinant of the contraction/relaxation state of bronchial smooth muscle. In the present study we investigated the relationship between bronchial reactivity, assessed by methacholine-provocation test, and magnesium concentrations both at extracellular and intracellular levels measured by spectrophotometry. Twenty-two patients with mild-to-moderate asthma and 38 non-asthmatic subjects with allergic rhinitis (24 all…

AdultHypersensitivity ImmediateIntracellular FluidMalemedicine.medical_specialtyAllergyErythrocytesParietariachemistry.chemical_elementBronchial Provocation TestsBronchoconstrictor AgentsInternal medicinemedicineHumansMagnesiumMethacholine ChlorideAsthmaAnalysis of VariancebiologyMagnesiumbusiness.industryGeneral MedicineSmooth muscle contractionbiology.organism_classificationmedicine.diseaseAsthmaBronchodilatationEndocrinologychemistryBronchial hyperresponsivenessImmunologyPollenFemaleBronchial HyperreactivitybusinessIntracellularClinical Science
researchProduct

Comparison of the effects of salmeterol and salbutamol on clinical activity and eosinophil cationic protein serum levels during the pollen season in …

1995

In atopic asthma there is strong evidence of eosinophils playing an active role in pathogenesis. Some investigations demonstrated that eosinophil cationic protein (ECP) serum levels increased in atopic patients with asthma during pollen season.The aim of the study was to evaluate the effects of short-term (1 week) beta 2-agonist treatment on lung function and eosinophil activity in asthmatic patients.We used an open, randomized, cross-over design to compare the effects of salbutamol (200 micrograms q.i.d.) and salmeterol (50 micrograms b.i.d.) on peak expiratory flow rate (PEFR), blood eosinophil count and serum levels of ECP as a measure of eosinophil activity in 20 mild atopic asthmatics.…

AdultHypersensitivity ImmediateMalemedicine.medical_specialtymedicine.drug_classImmunologyCell CountPeak Expiratory Flow RateLeukocyte CountRibonucleasesimmune system diseasesForced Expiratory VolumeBronchodilatorInternal medicinemedicineHumansImmunology and AllergyAlbuterolEosinophil degranulationSalmeterol XinafoateAsthmaEosinophil cationic proteinCross-Over Studiesbusiness.industryEosinophil Granule ProteinsRhinitis Allergic SeasonalBlood ProteinsEosinophil Granule ProteinsMiddle Agedrespiratory systemEosinophilmedicine.diseaseAsthmarespiratory tract diseasesEosinophilsEndocrinologymedicine.anatomical_structureSalbutamolPollenFemaleSalmeterolbusinesscirculatory and respiratory physiologymedicine.drugClinical <html_ent glyph="@amp;" ascii="&"/> Experimental Allergy
researchProduct

Psychodynamic Online Treatment Following Supportive Expressive Therapy (SET):Therapeutic Rationale, Interventions and Treatment Process.

2018

The feasibility of psychodynamic online treatments has remained an issue of debate. The paper presents rationale and technique of a psychodynamic online intervention discussing therapeutic process and alliance based on two case examples from an RCT.A weekly writing task is followed by individual feedback from the online therapist. Treatment focuses on a 'Core Conflict Relationship Theme' based on relationship episodes according to the wish of the patient, reactions of the others and reactions of the self. Maladaptive interpersonal interactions are worked through by supportive and expressive therapeutic interventions.Case reports from our study illustrate a productive therapeutic process wit…

AdultMale050103 clinical psychologyPsychotherapistWritingPsychological interventionlaw.inventionFeedbackSocial Skills03 medical and health sciencesNonverbal communicationFace-to-face0302 clinical medicineReturn to WorkRandomized controlled triallawHumans0501 psychology and cognitive sciencesInterpersonal Relations030212 general & internal medicineExpressive therapyPsychodynamic psychotherapyInternetNegotiating05 social sciencesSocial SupportRehabilitation VocationalProfessional-Patient RelationsMiddle AgedPsychodynamicsPsychotherapyAllianceTherapy Computer-AssistedFemalePsychologyPsychotherapy PsychodynamicZeitschrift fur Psychosomatische Medizin und Psychotherapie
researchProduct

Examining patients' and other group members' agreement about their alliance to the group as a whole and changes in patient symptoms using response su…

2012

There is a lack of research examining patients' and other group members' agreement about their therapeutic alliance. In the present study, the person-group (P-G) fit model was adopted to predict that the group member symptom reduction will be greater when the group member's and the other group members' perceptions of their alliance to the group-as-a-whole fit and are high. In addition, the effect of disagreement between the group member and the other group members in their perceptions of the group alliance on the individual's outcome was investigated by using response surface analysis. Thirty-two patients from 5 long-term (> 1 year) psychodynamic group treatments were studied. Participants …

AdultMaleAdolescentPsychotherapeutic ProcessesSocial Psychologymedicine.medical_treatmentContext (language use)Group psychotherapyGroup (periodic table)Settore M-PSI/08 - Psicologia ClinicamedicineHumansInterpersonal RelationsIn patientMental DisordersGeneral MedicineMiddle AgedPsychodynamicsGroup ProcessesGroup treatmentPsychiatry and Mental healthClinical PsychologyTreatment OutcomeAllianceItalyGroup processPsychotherapy GroupRegression AnalysisFemalegroup alliance long-term groups actor–partner analysis surface analysisPsychologyAttitude to HealthClinical psychologyJournal of Counseling Psychology
researchProduct